I believe genentech released some data at the aao meeting which referred to a subset of patients that had a 40 improvement at 6 months
It is good news for genaera, because it shows what squalamine will be capable of doing without a shot in the eye every 4 weeks.
can you imagine what must happen to an eye if it has been injected once a month for 3 years (36 shots).
Look at the inhaled insulins. It has been shown to be effective for the length of the trial but the fda was concerned about the fact that lung function decreased about 2 percent after one year. The fda became concerned. They said if you lose 2 percent in 1 year do you lose another 2 percent in the second year or does it geometrically progress and you lose 4 percent the following year, and so on.
How can anyone really know the damage to the eyeball in a 1 year trial. The fda might become concerned about how many injections the eye can actually take, and ask for longer safety information.
that is my guess.
As far as oxgn, it appears to work and I would consider it for an investment, but in my opinion they appear to hype more than they should.
That last press release was an example. They found a person that improved with the drug and went into a whole diatribe about changing their opthamalic focus. What did they really say?
But that doesn't mean the drug won't work. I am just a little put off by them
I think you feel that way about avn. I am not as confident about the management at avn as I am in genr, but at avn the drug, neurodex, is in the second pivotal trial, which had great results in the first pivotal trial. So the drug works or it doesn't, but I won't have to wait long to find out.
With oxgn the drug is still very early in the development process to be worrying about management.
Market Data 
Markets 
AI
